GLD1.3
TIGETi003-A
General
Cell Line |
|
| hPSCreg name | TIGETi003-A |
| Cite as: | TIGETi003-A (RRID:CVCL_A5GE) |
| Alternative name(s) |
GLD1.3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
|
| Last update | 5th February 2021 |
| User feedback | |
Provider |
|
| Generator | San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) (TIGET) |
External Databases |
|
| BioSamples | SAMEA7807679 |
| Cellosaurus | CVCL_A5GE |
| Wikidata | Q107117092 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46, XX
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA8152190 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | http://dppm.gaslini.org/biobank |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ospedale San Raffaele Ethical Committe |
| Approval number | TIGET HPCT |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ospedale San Raffaele Ethical Committe |
| Approval number | TIGET HPCT |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type | |
| Source cell origin |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
| Passage number reprogrammed | 10 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | modified mRNA |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| Medium |
Other medium:
Base medium: StemMACS iPSC brew
Main protein source: Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SOX2 |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
|||
| KLF4 |
Yes |
|
|
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
In vivo teratoma
In vitro spontaneous differentiation
In vivo teratoma
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX
Passage number: 16
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.